Company news

Viking Therapeutics, Inc. news in 2025

Viking Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

November 18, 2025

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

November 5, 2025

Viking Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

October 28, 2025

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 21, 2025

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

October 20, 2025

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

October 14, 2025

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

August 18, 2025

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

July 22, 2025

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

July 15, 2025

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

June 24, 2025

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

April 22, 2025

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

April 15, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

March 25, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

March 10, 2025

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

March 10, 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

February 4, 2025

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

January 28, 2025

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

January 7, 2025

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025